» Articles » PMID: 21484104

Superior Long-term Outcomes After Surgery in Child-pugh Class a Patients with Single Small Hepatocellular Carcinoma Compared to Radiofrequency Ablation

Overview
Journal Hepatol Int
Publisher Springer
Specialty Gastroenterology
Date 2011 Apr 13
PMID 21484104
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: There are insufficient data comparing long-term prognoses after radiofrequency ablation (RFA) and surgery.

Methods: We compared the baseline characteristics and survival rates of patients (single, ≤3 cm, and Child-Pugh class A) treated surgically (n = 215) and with RFA (n = 255) from January 2000 to December 2007 at our institution.

Results: The surgery group was characterized by younger age, higher prevalence of HBsAg, less cirrhosis, and an increased chance of Child-Pugh score of 5 and CLIP score of 1, compared to the RFA group. During the median follow-up period of 42 months (range 1-109), the 3-, 5- and 7-year overall survival rates in the surgery group were 98, 94, and 94%, respectively, which were significantly higher than those in the RFA group (92, 87, and 76%, respectively, P = 0.002). The 3- and 5-year recurrence-free survival rates were 72 and 66%, respectively, in the surgery group, which were significantly higher than those in the RFA group (34 and 24%, respectively, P < 0.001). The superiority of the survival rates in the surgery group persisted in most patients throughout the subgroup analysis, based on the Child-Pugh score and CLIP score. Multivariate analysis showed that age and surgery as a procedure type were the significant predictive factors for both overall survival [HR = 1.04 (CI 1.001-1.08), P = 0.047 for age; HR = 2.97 (CI 1.19-7.45), P = 0.02 for surgery] and recurrence-free survival [HR = 1.02 (CI 1.01-1.04), P = 0.01 for age; HR = 2.44 (CI 1.76-3.37), P < 0.001 for surgery].

Conclusions: The long-term outcome after surgery for Child-Pugh class A and single small HCC is superior to that after RFA.

Citing Articles

Primary treatments for solitary hepatocellular carcinoma ≤ 3 cm: A systematic review and network meta-analysis.

Kim S, Kim K, Na B, Kim S, Oh R Ann Hepatobiliary Pancreat Surg. 2024; 28(4):397-411.

PMID: 39175140 PMC: 11599817. DOI: 10.14701/ahbps.24-103.


Comparison of liver resection and radiofrequency ablation in long-term survival among patients with early-stage hepatocellular carcinoma: a meta-analysis of randomized trials and high-quality propensity score-matched studies.

Hu L, Lin J, Wang A, Shi X, Qiao Y World J Surg Oncol. 2024; 22(1):56.

PMID: 38369480 PMC: 10875898. DOI: 10.1186/s12957-024-03330-8.


Thermal ablation versus liver resection for hepatocellular carcinoma in patients with cirrhosis: a systematic review and meta-analysis of propensity-score matched studies.

Wei Q, Xiong S, Luo W, Liang M, Luo B Clin Exp Med. 2024; 24(1):32.

PMID: 38300338 PMC: 10834626. DOI: 10.1007/s10238-023-01285-w.


Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis.

Wade R, South E, Anwer S, Sharif-Hurst S, Harden M, Fulbright H Health Technol Assess. 2023; 27(29):1-172.

PMID: 38149643 PMC: 11017143. DOI: 10.3310/GK5221.


Comparable and Complimentary Modalities for Treatment of Small-Sized HCC: Surgical Resection, Radiofrequency Ablation, and Microwave Ablation.

Wicks J, Dale B, Ruffolo L, Pack L, Dunne R, Laryea M J Clin Med. 2023; 12(15).

PMID: 37568408 PMC: 10419984. DOI: 10.3390/jcm12155006.


References
1.
Hasegawa K, Makuuchi M, Takayama T, Kokudo N, Arii S, Okazaki M . Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol. 2008; 49(4):589-94. DOI: 10.1016/j.jhep.2008.05.018. View

2.
Marin-Hargreaves G, Azoulay D, Bismuth H . Hepatocellular carcinoma: surgical indications and results. Crit Rev Oncol Hematol. 2003; 47(1):13-27. DOI: 10.1016/s1040-8428(02)00213-5. View

3.
Fong Y, Sun R, Jarnagin W, Blumgart L . An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg. 1999; 229(6):790-9; discussion 799-800. PMC: 1420825. DOI: 10.1097/00000658-199906000-00005. View

4.
Livraghi T . Guidelines for treatment of liver cancer. Eur J Ultrasound. 2001; 13(2):167-76. DOI: 10.1016/s0929-8266(01)00129-x. View

5.
Makuuchi M, Kokudo N . Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. World J Gastroenterol. 2006; 12(5):828-9. PMC: 4066144. DOI: 10.3748/wjg.v12.i5.828. View